Silence of EIF4G2 is available to stimulate ovarian cancer (OC) patients to regain chemosensitivity to paclitaxel [34], and strengthen the sensitivity of cisplatin chemotherapy in NSCLC [35]. This evidence concerns the gene EIF4G2 and ovarian carcinoma.